Product Information
PERINDOPRIL ERBUMINE 8 MG TAB is a generic product labeled by Aurobindo Pharma Limited, priced at $0.5420 per EA under NDC 65862028801. Its NADAC has been published 623 times since Nov 28, 2013.
FDA first approved this application on Nov 10, 2009.
Strength
8 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862028801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PERINDOPRIL ERBUMINEApproval Type
Generic (ANDA)
FDA Application
ANDA079070FDA Approved
11/10/2009
On Market Since
11/10/2009
Pharmacological Classes
Price Statistics
The NADAC for PERINDOPRIL ERBUMINE 8 MG TAB has been published 623 times since Nov 28, 2013, and over the history we have for it it has risen 5.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5420 per EA |
|---|---|
| All-time high | $0.6505 (Aug 14, 2019) |
| All-time low | $0.4502 (Jan 22, 2020) |
| 52-week high | $0.6214 |
| 52-week low | $0.5420 |
| Median price | $0.5437 |
| Average price | $0.5440 |
| Largest weekly change | +43.9% (Jul 17, 2019) |
| Weeks tracked | 623 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Perindopril Erbumine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Perindopril Erbumine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PERINDOPRIL ERBUMINE 8 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for PERINDOPRIL ERBUMINE 8 MG TAB, manufactured by Aurobindo Pharma Limited, is $0.5420 per EA (NDC 65862028801), effective Sep 30, 2026.
How has the price of PERINDOPRIL ERBUMINE 8 MG TAB changed over time?
Over the history we have for it, the NADAC for PERINDOPRIL ERBUMINE 8 MG TAB has risen 5.6%. It has been tracked across 623 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PERINDOPRIL ERBUMINE 8 MG TAB?
Since Nov 28, 2013, the NADAC for PERINDOPRIL ERBUMINE 8 MG TAB has ranged from a low of $0.4502 (Jan 22, 2020) to a high of $0.6505 (Aug 14, 2019), with a median of $0.5437 per EA.
Are there cheaper alternatives to PERINDOPRIL ERBUMINE 8 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of PERINDOPRIL ERBUMINE 8 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PERINDOPRIL ERBUMINE 8 MG TAB?
PERINDOPRIL ERBUMINE 8 MG TAB (NDC 65862028801) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.